Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent

This study is currently recruiting participants.

Verified by Mayo Clinic, September 2005

Sponsors and Collaborators:	Mayo Clinic Engineers & Doctors Wallsten Medical Group
Information provided by:	Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00166361

Purpose

The purpose of this study is to evaluate the safety and efficacy of the Memokath 051 ureteral stent as a long-term temporary and minimally invasive means of providing ureteral drainage in the setting of malignant extrinsic ureteral obstruction secondary to inoperable abdominal or pelvic malignancies. Up to 15 adults who have extrinsic ureteral obstruction secondary to an inoperable abdominal or pelvic malignancy and need ureteral stent drainage will undergo outpatient placement of the ureteral stent. Ongoing monitoring will continue for as long as the stent is in place.

Condition	Intervention
Ureteral Obstruction	Device: Memokath 051 Ureteral Stent

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment
Official Title:	Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Treatment efficacy in relief of extrinsic ureteral obstruction in comparison to historic efficacy of standard double-J plastic ureteral stents as cited in the urologic literature
Perioperative and postoperative complications and side effect profiles, including failure of stent insertion, complications of stent insertion, and postoperative complications

Estimated Enrollment:	25
Study Start Date:	March 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Presence of extrinsic ureteral obstruction secondary to inoperable pelvic or abdominal malignancy.
Life expectancy greater than 4 months.
Adult patient (18 years of age or older)
Preoperative medical examination clearing the patient for general anesthesia
No active urinary tract infection by urinalysis and urine culture

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00166361

Locations

United States, Minnesota
Mayo Clinic	Recruiting
Rochester, Minnesota, United States, 55905
Contact: Karla A Knoke-Sandoe 507-284-3369
Principal Investigator: Lance A Mynderse, M.D.

Sponsors and Collaborators

Mayo Clinic

Engineers & Doctors Wallsten Medical Group

Investigators

Principal Investigator:

Lance A Mynderse, M.D.

Mayo Clinic

More Information

Study ID Numbers:	255-03
Study First Received:	September 12, 2005
Last Updated:	January 26, 2006
ClinicalTrials.gov Identifier:	NCT00166361
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Urologic Diseases
Ureteral Obstruction
Neoplasm Metastasis
Ureteral Diseases

ClinicalTrials.gov processed this record on January 15, 2009